- CEO
- Jin Sheng Lin
- Full Time Employees
- 26
- Sector
- Health technology
- Industry
- Pharmaceuticals: generic
- Address
- George Town Cayman Islands
- IPO Date
- Mar 31, 2010
- Business
- CXI Healthcare Technology Group Limited operates as an investment holding company that manufactures, processes, distributes, and markets traditional Chinese medicine (TCM)-based health foods, functional dietary supplements, raw botanical ingredients, and personal care products. The company operates through several core business divisions: Health Food Products, Raw Material Trading, Tea Products, and Cosmetics and Personal Care. Its comprehensive product portfolio includes TCM-based nutritional supplements in various delivery formats, such as Cordyceps Sinensis capsules, lingzhi mushroom formulations, dietary tablets, concentrated herbal granules, and oral functional tonics marketed under proprietary brands including Wellspring of Life and Yuan Kang; processed teas and loose-leaf products, including specialty Jiang tea, oolong tea, and green tea varieties; wholesale raw botanical materials and active herbal ingredients for commercial clients; and functional skincare and cosmetic products, including hydrating sunscreens, facial serums, and anti-aging topicals under the Kimparis Ellabie line. CXI Healthcare Technology Group distributes its offerings across the People's Republic of China and export markets through a nationwide distribution network, retail pharmacy chains, authorized specialty dealers, and major domestic and cross-border e-commerce platforms such as Tmall Global, JD.com, and Douyin. Founded in 2009 and listed on the KOSDAQ market of the Korea Exchange, the company is headquartered in Grand Cayman, Cayman Islands, and conducts its primary manufacturing, research, and operating activities through Chinese operating subsidiaries, including Fujian Jinshan Da Dao Health Technology Group Co., Ltd. and Fujian Wellspring of Life Bioengineering Co., Ltd. In recent developments, the company officially changed its corporate name from CKH Food & Health Limited to CXI Healthcare Technology Group Limited in October 2023 to reflect a strategic pivot toward integrated healthcare solutions and biotechnology. The company has expanded its multi-channel digital retail strategy via live-commerce streaming, broadened its personal care portfolio, and established research and technological partnerships with research institutes, including affiliates of the Chinese Academy of Sciences and Xiamen University, to advance TCM product R&D and explore AI-driven health diagnostic support. Additionally, between 2024 and 2026, the company completed multiple private placement equity rounds and capital restructuring initiatives to optimize its balance sheet and fund strategic business expansions.